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Abstract
Background: ALCAM (activated leukocyte cell adhesion molecule, CD166, MEMD) is a transmembrane protein of
immunoglobulin superfamily (Ig-SF) and plays an important role in human malignant melanoma progression and
formation of locoregional and distant metastases. The study using melanoma cell lines showed that overexpression
of ALCAM is directly related with the increase of cytoaggregation and the ability to form cell nests. The aim of
the study was to assess the expression and intracellular localization of ALCAM in primary skin melanomas and
metastatic lesions from regional lymph nodes. Also, prognostic significance of ALCAM expression in primary tumor
cells and metastatic lesion cells was evaluated in the context of 5-year observation.
Methods: Formalin-fixed paraffin-embedded tissue specimens from 104 primary cutaneous melanomas and 16
regional lymph nodes metastases were studied for the expression of ALCAM measured by immunohistochemistry.
Results: We demonstrate that high ALCAM expression in primary melanoma cells (IRS ≥8) is strongly correlated
with unfavorable prognosis as compared with patients with lower ALCAM immunoreactivity in tumor compartment
as regards cancer specific overall survival (CSOS) (P = 0.001) and disease free survival (DFS) (P < 0.001). Additionally
lower ALCAM immunoreactivity in nodal metastatic foci was significantly statistically correlated with deeper
melanoma invasion in the primary tumor according to Clark scale (P = 0.032). It was also found that decreased
ALCAM expression (IRS <8) in nodal metastases shows a trend related with a correlation with shorter cancer specific
overall survival (P = 0.083). Statistically significant correlations were also demonstrated between the presence of
ulceration and decreased intensity of lymphocytic inflammatory infiltration and a high percentage of ALCAM-positive
cells (P = 0.035, P = 0.01, respectively).
Conclusions: High ALCAM expression in melanoma cells of the primary tumor can be used as a marker of negative
outcome and may indicate a more invasive phenotype of cancer cells, which would require a more intensive
therapeutic strategy. Low expression of ALCAM in regional lymph node metastases is a feature associated with
unfavorable prognosis in patients with cutaneous melanoma. Our study is the first one to evaluate the effect of
increased ALCAM expression on long-term survival in melanoma patients.
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Background
The unique local homeostasis maintained between kerati-
nocytes, melanocytes and the extracellular matrix that sur-
rounds them has a key role in the regulation of melanocyte
growth and proliferation [1, 2]. Each melanocyte is esti-
mated to directly interact and regulate approximately 36
keratinocytes [3]. Melanocyte growth is regulated by the
surrounding keratinocytes through various control me-
chanisms. The two most important involve: (1) paracrine
growth factors secreted into the extracellular environment,
and (2) intercellular communication of melanocytes and
keratinocytes with extracellular matrix proteins via mul-
tiple adhesion molecules [4]. All disturbances of this
extremely precise homeostasis may lead to abnormal ex-
pression of adhesion proteins and molecules involved in
intercellular communication, which may in turn initiate
melanomagenesis.
In the initial stages of melanoma growth and progression,
keratinocytes lose their ability to regulate melanocytes as a
result of the three main pathobiochemical processes that
occur in melanoma cells. One of them involves reduced ex-
pression of receptors such as E-cadherin, P-cadherin and
connexin which are crucial for melanocyte-keratinocyte
communication [4, 5]. The second mechanism via which
the epithelium cells lose control of melanocytes is directly
connected with overexpression of receptor proteins and
signaling molecules involved in cytological interactions of
the melanocyte-fibroblast type. It was demonstrated that
increased immunoreactivity of proteins e.g. N-cadherin,
Mel-CAM and ZO-1 (zonula occludens protein-1) is related
with increased invasive potential of melanoma cells [4, 6].
The last mechanism that allows melanocytes to escape
from control by keratinocytes involves loss of expression of
proteins anchoring melanocytes to the basement mem-
brane [4, 7].
Maintaining intercellular adhesion is a necessary process
during invasion of cancer cell nests [8]. However, adhesion
deregulation must be one of the stages of metastatic foci
development. It is a key moment in which single cells or
nests use the changed profile of adhesion molecules ex-
pression to occupy new areas, which initiates the spread of
cancer. Adhesion protein spectrum whose immunoreac-
tivity panel would be characteristic for invasive melanoma
cells has not been identified so far.
ALCAM (activated leukocyte cell adhesion molecule,
CD166, MEMD) is a transmembrane protein of immu-
noglobulin superfamily (Ig-SF) [9]. The gene encoding
ALCAM is located on the long arm of chromosome 3 and
it is organized into 16 exons [10]. Ultrastructural studies
show it has 27 % homology with adhesion molecule found
on the surface of MUC18/Mel-CAM/CD146 melanoma
cells, which promotes progression of this cancer and
formation of locoregional and distant metastases [11]. The
key element of ALCAM molecule that regulates its
adhesive capacity is the extracellular part composed of five
immunoglobulin-like domains (D1-D5) [12]. There is also
a transmembrane domain and an intracellular short C-
terminal tail. At first, ALCAM was identified as a ligand
for CD6 receptor (heterotypic interaction, ALCAM-CD6),
and its expression was observed on the surface of leuko-
cytes, fibroblasts, epithelial and nerve cells [10, 13]. Other
cytophysiological analyses revealed the existence of func-
tional homotypic interactions of the ALCAM-ALCAM
type which were identified in CD6-negative melanoma cell
lines [14]. The study using melanoma cell lines showed
that overexpression of ALCAM is directly related with the
increase of cytoaggregation and the ability to form cell
nests [14]. Additionally, it was found that the homotypic
ALCAM-ALCAM interaction plays a key role during
intercellular adhesion. Interestingly, Degen et al. [14]
proved that ALCAM expression is correlated with in-
creased metastatic potential of melanoma cell lines.
So far, little is known about regulating expression of
ALCAM on the gene level. It was showed that the
ALCAM promoter contains a sequence binding NF-κB
and AP-1 (activator protein 1) which act as transcription
factors [15, 16]. Studies into the potential effects of NF-
κB on ALCAM expression demonstrated that its binding
to the promoter sequence of ALCAM gene enhances the
immunoreactivity of the resulting protein product [15].
In turn, the effect of AP-1 family, and specifically overex-
pression of Fra-2 (Fos-related antigen 2) is closely related
with the resulting decreased production of ALCAM [16].
Interesting conclusions concerning new biological func-
tions and role of melanoma progression were drawn by
Luntner et al. [17] based on their experiment. ALCAM is
instrumental for the formation of a triple complex on the
surface of melanoma cells MT1-MMP/TIMP-2/pro-MMP-
2 and the subsequent conversion of inactive form of
metalloproteinase 2 (pro-MMP-2) into an active form
responsible for the degradation of extracellular matrix
and contributes to the formation of nodal and distant
metastases [17]. Inhibition of ALCAM expression re-
sulted in significantly decreased MMP-2 activity, and
thus in decreased metastatic potential. Pooled analysis
of results has allowed establishing a hypothesis that
ALCAM is involved in regulating proteolysis via some
still unknown mechanisms and seems to act as a cell-
surface sensor for invasive growth [15, 17].
The aim of the study was to assess the expression
and intracellular localization of ALCAM in 104 primary
skin melanomas and 16 metastatic lesions from re-
gional lymph nodes. Also, prognostic significance of
ALCAM expression in primary tumor cells and meta-
static lesion cells was evaluated in the context of 5-year
observation. Correlations were also analyzed between
ALCAM immunoreactivity parameters and detailed clini-
copathological parameters such as Breslow thickness and
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Clark level, presence of nodal and distant metastases,
recurrence of primary tumor, mitotic rate, ulceration,
lymphocytic inflammatory infiltration, regression and
microsatellitosis.
Methods
Patients and ethics statements
The study group consisted of 104 patients with CMM,
who were diagnosed between 2005 and 2010 and treated
in the Lower Silesian Oncology Center in Wrocław,
Poland. Additionally, tissue material obtained from 16
nodal metastatic foci was included in the study. The
group was selected on the basis of tissue material (paraf-
fin blocks and histopathology slides) and the availability
of medical documentation. Comprehensive clinical data
were obtained from archival medical records. The diag-
nostic and therapeutic procedures utilized were deter-
mined from medical records in the Oncology Outpatient
Clinic of the Lower Silesian Oncology Center and data
provided by the Lower Silesian Cancer Registry and Civil
Register Office. The retrospective study was approved by
the Ethical Committee of the Wroclaw Medical University,
Poland.
Patients enrolled in the study were treated by then-
available methods. Excisional biopsy of the primary
lesion was performed. Once cutaneous melanoma was
diagnosed in histopathological examination, the primary
procedure was extended by excising the scar with a margin
of 5, 10 or 20 mm of unaffected skin depending on Bre-
slow thickness and primary tumor location, if any. If
nodal metastases (cN0) were not clinically manifested
and Breslow thickness was above 1 mm (>pT1a), senti-
nel lymph node biopsy (SNLB) was performed. When
metastases were observed in the regional lymph nodes
(found either clinically or by SLNB), lymphadenectomy
was performed.
The clinicopathological profile of patients included the
following parameters: age and gender, primary tumor lo-
cation, tumor stratification according to AJCC (pT),
presence or absence of nodal (pN) and distant (pM) me-
tastases, information on disease recurrence and sentinel
lymph node biopsy (SLNB) procedures (Table 1).
Tumor samples and histopathological evaluation
Tumor specimens were fixed in 10 % buffered formalin
and embedded in paraffin. All haematoxylin and eosin
stained sections were examined by two pathologists. The
parameters of the primary tumor recorded in pathology
reports were Breslow thickness, Clark level, growth phase,
histologic type, mitotic rate (number of mitotic figures
per 1 mm2), presence of ulceration, lymphangioinvasion,
microsatellitosis, intensity of lymphocytic inflammatory
infiltrate (TILs, tumor-infiltrating lymphocytes) and micro-
scopic evidence of regression (Table 2).
Immunohistochemistry
Formalin-fixed, paraffin embedded tissue was freshly cut
(4 μm). The sections were mounted on superfrost slides
(Menzel Glaser, Germany), dewaxed with xylene, and grad-
ually hydrated. The activity of endogenous peroxidase was
blocked by 5 mins exposure to 3 % H2O2. The sections
were boiled for 15 mins at 250 W in Antigen Retrieval So-
lution (DakoCytomation, Denmark). Immunohistochemical
reactions were then performed using monoclonal antibody
detecting ALCAM (clone 10F1G12; Abgent, United
Kingdom). The tested sections were incubated with anti-
bodies for 1 h at room temperature. The subsequent
incubations involved biotinylated antibodies (15 mins at
room temperature) and streptavidin-biotinylated peroxid-
ase complex (15 mins at room temperature) (LSAB+,
HRP, DakoCytomation, Denmark). DAB (Vector Labora-
tories, UK) was used as a chromogen (10 mins at room
Table 1 Clinicopathological characteristics of the patients
Clinicopathological characteristics No (%)
All patients 104 (100.0)
Age in years (21–79)






Upper extremity 18 (17.3)








Sentinel lymph node biopsy status (SNLB) 60 (57.7)
No metastases (SNLB-) 48 (80.0)
Metastases present (SNLB+) 12 (20.0)
Regional lymph nodes status (pN)
No metastases (pN-) 86 (82.7)
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temperature). All sections were counterstained with
Meyer’s hematoxylin. In every case control reactions
were performed, with the relevant antibody substituted
by Primary Mouse Negative Control (DakoCytomation,
Denmark).
Evaluation of reaction intensity
The intensity of the immunohistochemical reaction was
estimated independently by two pathologists. Doubtful
cases were re-evaluated under a double-headed micro-
scope and staining was discussed until consensus was
achieved.
ALCAM expression was observed only in melanoma
cells both in tissue material obtained from the primary
tumor and nodal metastatic foci. No ALCAM immunore-
activity was identified in stromal compartment of tumor
or lymphocytes from regional lymph nodes. Cancer cells
of the primary tumor were found to exhibit two patterns
of expression. Membranous-cytoplasmic localization was
particularly visible in cell nests/cytoaggregates, while dif-
fuse cytoplasmic expression without the membrane com-
ponent was observed in those cancer cells which did not
form evident cell nests but were a pool of scattered melan-
oma cells (Fig. 1 a-d). Metastatic cells displayed predomin-
antly diffuse cytoplasmic expression (Fig. 1 e-f).
The expression of ALCAM protein was calculated
using a semi-quantitative method. Two immunohisto-
chemical reaction parameters were considered when
evaluating the expression of the foregoing proteins: the
percentage of cells with a positive cytoplasmic reaction
(the percentage of reactive tissue) and the reaction in-
tensity. The final immunohistochemical reaction results
are expressed according to the semi-quantitative IRS
(ImmunoReactive Score) scale devised by Remmele and
Stenger [18]. This scale assigns a score for the percent-
age of cells demonstrating reaction (0–4 points) and for
reaction intensity (0–3 points). The final result is the
product of the scores for these two parameters (0–12
points) and is referred to as an IRS factor or score.
Statistical analysis
Statistical analysis was performed using the Statistica
10.0 and IBM SPSS 21 software packages. Overall sur-
vival (OS) was defined as the time between the primary
surgical treatment and death, and OS was censored at
last follow-up for patients who were still alive. Disease-
free survival (DFS) was defined as the time between the
primary surgical treatment and the date of relapse. DFS
was censored at the last follow-up for patients who sur-
vived without disease recurrence or at the date of non-
cancer associated death. Cancer-specific overall survival
(CSOS) was defined as the time between the primary
surgical treatment and cancer-associated death, and was
censored at the last follow-up for surviving patients.
A χ2 test, exact Fisher test in the case of 2 × 2 tables,
and Spearman rank correlation were used to analyze
associations between mitotic rate and the presence of
ulceration and clinicopathological parameters. Differences
between the means were tested with a nonparametric test
(Mann–Whitney U test and Kruskal-Wallis test), the
Table 2 Histopathological parameters of primary tumors
Histopathological parameters of the primary tumor No (%)
Breslow thickness
<1 mm 34 (32.7)
1.01-2.00 mm 20 (19.2)
2.01-4.00 mm 27 (26.0)








Superficial spreading melanoma (SSM) 68 (65.4)
Nodular malignant melanoma (NMM) 32 (30.8)
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log-rank test was used to compare survival in two
groups, the overall survival rate was estimated by the
Kaplan-Meier method and the influence of explanatory
variables on death risk was analyzed by means of the
Cox proportional hazard regression. P values <0.05 were
considered statistically significant.
Results
ALCAM expression in primary tumors and nodal metastases
ALCAM expression, defined as IRS > 0, was identified in
96 primary tumors (92.3 % of cases). In 8 cases (7.7 %) no
ALCAM immunoreactivity was detected in cancer cells.
High ALCAM expression, defined as IRS ≥ 8 was detected
in 18 cases (17.3 %). The mean IRS was 4.39 ± 2.64. Ana-
lysis of melanoma cells obtained from nodal metastatic
foci showed the presence of ALCAM in 14 out of 16 cases
(87.5 %). High ALCAM expression, defined as IRS ≥ 8 was
detected in 5 cases (31.3 %). The mean IRS in nodal me-
tastases was 4.69 ± 4.01.
Correlations between ALCAM expression in primary
tumor and lymph node metastases with histopathological
features of primary melanoma
Increased ALCAM expression (defined as increased IRS)
in melanoma cells in primary tumor is closely correlated
with higher Breslow thickness and higher Clark level
(P = 0.008 and P = 0.001, respectively). Similar correlations
were observed for a percentage of ALCAM-positive can-
cer cells, where a higher number of melanoma cells show-
ing ALCAM expression (0-75 % versus 75 %) was closely
Fig. 1 Immunohistochemically visualized expression of ALCAM in cutaneous melanoma. Lack of ALCAM immunoreactivity in melanoma cells from
primary tumor (a, 200×, hematoxylin). Cytoplasmic distribution of ALCAM in melanoma cells from primary tumor (b, IRS 6, 400×, hematoxylin). High
cytoplasmic ALCAM reactivity in primary melanoma (c, IRS 12, 400×, hematoxylin). Predominantly membranous-cytoplasmic expression of ALCAM in
different sizes of nests composed of malignant melanoma cells from primary tumors (d, 400×, hematoxylin). Immunohistochemical pattern of ALCAM
expression in regional lymph nodes metastases. Low ALCAM immunoreactivity in metastatic melanoma cells (e, 400×, hematoxylin). High cytoplasmic
reactivity of ALCAM in regional lymph node metastases (f, 200×, hematoxylin)
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related with a deeper invasion into the skin layers, both
according to Breslow and Clark scales (P = 0.003 and P =
0.026, respectively) (Table 3).
Statistically significant correlation was also demon-
strated between the presence of ulceration and a high
percentage of ALCAM-positive cells (P = 0.035). A
Fig. 2 Kaplan-Meier analysis of the impact of ALCAM expression in 104 primary tumors (a-d) and 16 nodal metastases (e, f) on 5-year survival in
melanoma patients. Increased ALCAM expression (IRS) in the primary tumor strongly correlated with shorter CSOS (a) and DFS (b); analogous
associations with shorter CSOS (c) and DFS (d) were observed for increased percentage of ALCAM-(+) cells in the primary tumor. Survival analysis
of 16 cases of nodal metastases revealed a paradoxical trend relating decreased ALCAM expression (IRS) in melanoma metastases with shorter
CSOS (e), however, there was no association with DFS (f)
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tendency was observed that increased number of cells
with ALCAM immunoexpression is correlated with
a higher mitotic rate which is an independent bad
prognostic factor associated with high proliferative
potential of the primary tumor (P = 0.05) (Table 3).
Interestingly, statistical analysis showed that higher
percentage of ALCAM-positive melanoma cells is closely
related with decreased intensity of lymphocytic inflamma-
tory infiltration (P = 0.01).
Analysis of ALCAM expression in nodal metastatic
foci demonstrated that lower percentage of positive cells
is closely correlated with deeper infiltration of the
melanoma in the primary tumor according to Clark scale
(P = 0.032) (Table 3).
Correlations between ALCAM immunoreactivity and
clinicopathological parameters
Increased ALCAM expression, defined as higher per-
centage of ALCAM-positive cells and higher IRS, is
strongly correlated with higher extension as per pT
parameter identifying the primary tumor (P = 0.0001 and
P = 0.016, respectively). Additionally, enhanced intensity
of immunohistochemical reaction related with ALCAM
detection shows a trend related with a correlation with
cancer recurrence (P = 0.082) (Table 3). No other statisti-
cally significant correlations were identified between
ALCAM expression parameters and other clinical fea-
tures such as tumor location, age or sex (Table 3).
Analysis of ALCAM expression effect on 5-year survival in
melanoma patients
High ALCAM expression in cancer cells of the primary
tumor (IRS ≥8) is closely correlated with unfavorable
prognosis in cutaneous melanoma patients as regards
cancer specific overall survival and particularly disease free
survival (P = 0.001 and P < 0.001, respectively) (Fig. 2).
Additionally, survival analysis showed that a high percent-
age of ALCAM-positive cells (>75 %) may be considered
Fig. 3 Kaplan-Meier analysis of the impact of ALCAM expression in primary tumors in melanoma patients without regional lymph node
metastases (a, b) and in patients with negative SLNB status (c, d). Survival analysis showed that in patients without locoregional nodal metastases
increased ALCAM expression (IRS) is associated with shorter CSOS (a) and DFS (b); similarly, also in SLNB-negative patients, increased ALCAM
expression (IRS) was related to shorter CSOS (c) and DFS (d)
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an unfavorable prognosticator (P = 0.007 for CSOS and
P = 0.025 for DFS) (Fig. 2).
Paradoxically, analysis of 16 cases of lymph node me-
tastases demonstrated a trend correlating shorter CSOS
with decreased ALCAM expression (IRS < 8) in meta-
static cancer cells. No such correlation was found for
DFS (Fig. 2).
In patients without regional lymph nodes metastases
(N-) a statistically significant correlation was observed
between increased ALCAM expression in the primary
tumor and shorter CSOS and DFS (P = 0.006 and P =
0.001, respectively). A similar correlation was noted for
patients with a negative sentinel lymph node biopsy
status (SLNB-) (P = 0.001 and P = 0.004 respectively for
CSOS and DFS) (Fig. 3).
Univariate and multivariable Cox analysis of
clinicopathological parameters affecting survival of
melanoma patients
Independent bad prognostic factors in cutaneous melan-
oma patients that were showed to have a statistically sig-
nificant effect on survival are the recognized clinical
parameters: (1) microscopic primary tumor advancement
(pT); (2) presence of distant metastasis (pM) and (3) Bre-
slow thickness (Table 4). Interestingly, multivariable Cox
analysis revealed the effect of high percentage of ALCAM-
Table 3 Correlations between clinicopathological and histopathological characteristics and ALCAM expression parameters in primary
tumors and nodal metastases
ALCAM expression – primary tumor ALCAM expression – nodal metastasis
Clinicopathological parameters %a Intb IRSc %a Intb IRSc
pTad 0.0001 0.245 0.016 0.257 0.977 0.659
pNe 0.211 0.228 0.805 0.439 0.952 0.870
Distant metastasese 0.145 0.886 0.152 0.257 0.596 0.749
Recurrencee 0.161 0.082 0.705 0.705 0.906 0.669
Aged 0.368 0.555 0.303 0.467 0.866 0.793
Gendere 0.452 0.596 0.699 0.166 0.724 0.699
Primary tumor locationf 0.412 0.470 0.586 0.779 0.864 0.992
Histopathological parameters % Int IRS % Int IRS
Breslow thicknessd 0.003 0.342 0.008 0.340 0.865 0.744
Clark leveld 0.026 0.912 0.001 0.032 0.598 0.400
Growth phasee 0.422 0.714 0.568 100 % vertical growth phase
Histologic typef 0.523 0.082 0.749 0.529 0.906 0.709
Mitotic rated 0.050 0.163 0.536 0.834 0.825 0.976
Ulceratione 0.035 0.795 0.086 0.564 0.840 0.625
Lymphangioinvasione 0.523 0.379 0.480 0.439 0.147 0.274
Microsatellitosise 0.249 0.381 0.616 0.439 0.717 0.444
Tumor-infiltrating lymphocytes (TILs)f 0.010 0.389 0.451 0.967 0.359 0.549
Tumor regressione 0.761 0.364 0.771 100 % without regression
aPercentage of ALCAM-positive melanoma cells (0–4 points)
bIntenisty of immunohistochemical reaction (0–3 points)
cImmunoReactive Score (product of the scores for the percentage of positive cells and intensity of reaction (0–12 points)
dP value of Spearman rank correlation
eP value of Mann-Whitney’s U test
fP value of Kruskal-Wallis test
Statistically significant results (P < 0.05) are in bold font
Table 4 Survival prognosticators in cutaneous malignant melanoma patients – univariate and multivariable Cox proportional hazard
regression models
Clinicopathological parameters Univariate models Multivariable model
P value HR 95 % CI P value HR 95 % CI
Primary tumor (pT) <0.001 1.896 1.329-2.704 0.001 1.594 1.208-2.103
Distant metastases (pM) <0.001 7.070 2.648-18.873 0.001 6.406 2.089-19.647
Breslow thickness 0.004 1.161 1.049-1.284 0.033 0.773 0.610-0.980
High percentage of ALCAM(+) cells 0.032 2.317 1.075-4.995 0.079 2.028 0.922-4.463
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positive melanoma cells from the primary tumor as a
potential, independent prognostic factor, yet without
statistical significance (Table 4).
Discussion
Our study is the first one to evaluate the effect of in-
creased ALCAM expression on long-term survival in
melanoma patients. We demonstrate that high ALCAM
expression in primary tumor cancer cells (IRS ≥8) is
strongly correlated with unfavorable prognosis as com-
pared with patients with lower ALCAM immunoreactivity
in tumor compartment as regards cancer specific overall
survival (CSOS) (P = 0.001) and disease free survival (DFS)
(P < 0.001). Furthermore, the results were similar for a
high percentage (>75 %) of ALCAM-positive melanoma
cells in primary tumor (P = 0.007 and P = 0.025 for CSOS
and DFS, respectively). An important part of our study
was to evaluate the correlation between ALCAM expres-
sion in metastatic foci in regional lymph nodes and de-
tailed clinicopathological parameters. It was found that
decreased ALCAM expression (IRS <8) in nodal metasta-
ses shows a trend related with a correlation with shorter
cancer specific overall survival (P = 0.083). Additionally
lower ALCAM immunoreactivity in nodal metastatic foci
was significantly statistically correlated with deeper melan-
oma invasion in the primary tumor according to Clark
scale (P = 0.032).
A review of world literature (PubMed; 1970–2014; key
words: ALCAM, malignant melanoma) identified only 2
reports that were concerned with analysis of ALCAM
expression in tissue material obtained from cutaneous
melanoma patients using immunohistochemistry [9, 19].
Van Kempen et al. [9] performed a thorough immuno-
histochemical analysis of ALCAM expression in 38 be-
nign melanocytic lesions, 55 primary melanomas and 28
metastases (11 originating from the skin, 17 as nodal
metastatic foci). It was demonstrated that in the majority
of benign lesions (34/38) no ALCAM expression was
observed in melanocytes. Interestingly, no ALCAM im-
munoreactivity was observed in any of the early stage
melanomas (Clark I and II). As regards Breslow thick-
ness it was shown that over 70 % of over 1.5 mm thick
melanomas had increased ALCAM expression in cancer
cells [9]. These results are similar to ours in that in-
creased ALCAM expression in melanoma cells in the
primary tumor (defined as higher IRS and a high per-
centage of positive cells) was strongly correlated with
deeper thickness in Breslow scale and higher level in
Clark scale. Analysis of ALCAM immunoreactivity in
cancer cells from metastases brought interesting results
that were similar to ours because van Kempen et al. [9]
identified ALCAM expression in 42 % (7/17) of the
analyzed nodal metastatic foci while in our study we ob-
served high expression (defined as IRS ≥8) in 5 out of 16
nodal metastatic foci (32 %). Van Kempen et al. [9], due
to a different nature of the study (the article was only to
present ALCAM expression pattern in benign and ma-
lignant melanocytic lesions), did not discuss any correla-
tions with clinicopathological data or their bearing on
prognosis.
The study by Klein et al. [19] is the second report on
immunohistochemical analysis of ALCAM in melanoma.
It evaluates ALCAM reactivity in 71 benign melanocytic
lesions, 71 melanomas and 84 metastases. The authors
did not specify the type of metastatic foci they examined
(nodal or in parenchymal organs). Klein et al. [19] con-
firmed ALCAM expression in 11/71 of benign lesions,
37/70 of melanomas and 58/84 of metastases. At the
same time they observed that in melanomas and meta-
static foci ALCAM immunoreactivity was most intense.
Klein et al. [19] did not examine correlations with any
clinicopathological parameters, nor did they evaluate the
effect of ALCAM immunoexpression on long-term sur-
vival of cutaneous melanoma patients. The article fo-
cuses only on the description of ALCAM expression in a
relatively wide spectrum of melanocytic lesions.
Most reports say that homophilic ALCAM-ALCAM
interactions are more important in cytophysiology than
heterophilic CD6-ALCAM interactions. Interestingly,
the study by Swart et al. [20, 21] suggested, based on the
current knowledge of intercellular connections, that
homophilic ALCAM-ALCAM interactions from a theor-
etical point of view are generally not necessary for the
maintenance of cell adhesion if the proteins of cadherin
family and other adhesive glycoproteins work efficiently.
What is more, as shown by numerous reports, it is the
loss of expression of adhesion molecules that is strongly
correlated with cancer progression and formation of
nodal and distant metastases. Paradoxically, an opposite
situation occurs in the case of ALCAM adhesion protein,
where it is the upregulation and increase of homophilic in-
teractions is strongly correlated with melanoma progres-
sion (ALCAM paradox). It was showed in in vitro models
[12, 14, 15], and our results demonstrating that the up-
regulation of ALCAM in primary tumor and decreased
expression of ALCAM in melanoma cells from nodal
metastatic foci as the bad diagnostic indicators is the first
report of this kind and is based on the analysis of well-
documented clinical material and confirm experimental
considerations conducted during studies in cell lines and
using laboratory animals [12, 15].
In our opinion the different prognostic significance of
ALCAM expression in primary tumor and lymph node
metastasis should not be viewed as ALCAM paradox.
The involvement of ALCAM in melanoma progression
should be seen as composed of two stages [20, 21]. The
first stage involves ALCAM overexpression during inva-
sion of the dermis layers (depth of infiltration) by nests
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of cancer cells (which may be formed as a result of homo-
philic ALCAM-ALCAM interactions) (local growth stage),
while the second stage involves decreased ALCAM ex-
pression which facilitates invasion of single cells and for-
mation of metastatic foci in regional lymph nodes, which
greatly worsens prognosis. In our study in cancer cells
from the primary tumor we observed ALCAM expression
in membranous-cytoplasmic and cytoplasmic location,
dominantly in cell nests forming specific cytoaggregates,
while in cancer cells from nodal metastatic foci the only
pattern of intracellular distribution was cytoplasmic ex-
pression, which is in line with the considerations of the
structural-functional ALCAM analysis (two-stage model
of ALCAM expression). It must be stressed that it is a
hypothesis that needs to be supplemented and validated
empirically with a much larger study group and animal
models of metastasis, however, it is a voice in the discus-
sion and confirms the hypotheses concerning the role of
ALCAM in melanoma progression.
In spite of large scale multicenter research on cytobio-
chemistry and oncobiology of ALCAM, numerous ques-
tions remain that if answered could help to develop new,
promising treatment options and implement a more per-
sonalized treatment of melanoma patients.
Conclusions
Our study is the first one to evaluate the effect of in-
creased ALCAM expression on long-term survival in mel-
anoma patients. High ALCAM expression in melanoma
cells of the primary tumor can be used as a marker of
negative outcome and may indicate a more invasive
phenotype of cancer cells, which would require a more in-
tensive therapeutic strategy. Low expression of ALCAM
in regional lymph node metastases is a feature associated
with unfavorable prognosis in patients with cutaneous
melanoma.
Abbreviations
ALCAM: Activated leukocyte cell adhesion molecule; CMM: Cutaneous
malignant melanoma; CSOS: Cancer-specific overall survival; DFS: Disease-free
survival; Fra-2: Fos-related antigen 2; IRS: Immuno reactive score; OS: Overall
survival; SNLB: Sentinel lymph node biopsy; TILs: Tumor-infiltrating lymphocytes;
ZO-1: Zonula occludens protein-1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PD, MZ, AH, RM: study concepts and design; PD, MZ, RM: data acquisition;
PD, RM, MZ, ML, CK, AH: data analysis and interpretation; ML, CK: statistical
analysis; PD, RM: manuscript preparation and editing. All authors read and
approved the final manuscript.
Acknowledgements
This study was supported by Wroclaw Medical University research grant
ST-843and Pbmn157.
Author details
1Department of Pathomorphology and Oncological Cytology, Wroclaw
Medical University, Borowska 213, 50-556 Wroclaw, Poland. 2Lower Silesian
Oncology Centre, pl. Hirszfelda 12, 53-413 Wroclaw, Poland. 3Department of
Statistics, Wroclaw University of Economics, Komandorska 118-120, 53-345
Wroclaw, Poland. 4Department of Oncology and Division of Surgical
Oncology, Wroclaw Medical University, pl. Hirszfelda 12, 53-413 Wroclaw,
Poland.
Received: 25 September 2014 Accepted: 17 June 2015
References
1. Gordon PR, Mansur CP, Gilchrest BA. Regulation of human melanocyte
growth, dendricity, and melanization by keratinocyte derived factors.
J Invest Dermatol. 1989;92:565–72.
2. Hedley SJ, Wagner M, Bielby S, Smith-Thomas L, Gawkrodger DJ, MacNeil S.
The influence of extracellular matrix proteins on cutaneous and uveal
melanocytes. Pigment Cell Res. 1997;10:54–9.
3. Jimbow K, Quevedo Jr WC, Fitzpatrick TB, Szabo G. Some aspects of
melanin biology: 1950–1975. J Investig Dermatol. 1976;67:72–89.
4. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication
in melanocytes and melanoma. Pigment Cell Res. 2005;18:150–9.
5. Seline PC, Norris DA, Horikawa T, Fujita M, Middleton MH, Morelli JG.
Expression of E and P-cadherin by melanoma cells decreases in progressive
melanomas and following ultraviolet radiation. J Invest Dermatol.
1996;106:1320–4.
6. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M.
Up-regulated expression of zonula occludens protein-1 in human
melanoma associates with N-cadherin and contributes to invasion and
adhesion. Am J Pathol. 2005;166:1541–54.
7. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human
melanoma cells. Oncogene. 2003;22:3070–5.
8. Balzer EM, Konstantopoulos K. Intercellular adhesion: mechanisms for
growth and metastasis of epithelial cancers. Wiley Interdiscip Rev Syst Biol
Med. 2012;4:171–81.
9. van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP,
Swart GW. Activated leukocyte cell adhesion molecule/CD166, a marker of
tumor progression in primary malignant melanoma of the skin. Am J Pathol.
2000;156:769–74.
10. Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H,
Neubauer M, Pesando JM, Francke U, Hayens BF, Aruffo A. Cloning,
mapping, and characterization of activated leukocyte-cell adhesion
molecule (ALCAM), a CD6 ligand. J Exp Med. 1995;181:2213–20.
11. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor
progression in human melanoma, shows sequence similarity to the neural
cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad
Sci U S A. 1989;86:9891–5.
12. van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C,
Weidle UH, Van Muijen GN, Herlyn M, Bloemers HP, Swart GW.
Truncation of activated leukocyte cell adhesion molecule: a gateway to
melanoma metastasis. J Invest Dermatol. 2004;122:1293–301.
13. Patel DD, Wee SF, Whichard LP, Bowen MA, Pesando JM, Aruffo A, Haynes BF.
Identification and characterization of a 100-kD ligand for CD6 on human
thymic epithelial cells. J Exp Med. 1995;181:1563–8.
14. Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y,
Bloemers HP, Swart GW. MEMD, a new cell adhesion molecule in
metastasizing human melanoma cell lines, is identical to ALCAM
(activated leukocyte cell adhesion molecule). Am J Pathol. 1998;152:805–13.
15. Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a
new paradox in cancer. Transl Res. 2008;151:122–8.
16. Zhang G, Slaughter C, Humphries EH. v-rel Induces ectopic expression of an
adhesion molecule, DM-GRASP, during B-lymphoma development.
Mol Cell Biol. 1995;15:1806–16.
17. Lunter PC, van Kilsdonk JW, van Beek H, Cornelissen IM, Bergers M,
Willems PH, van Muijen GN, Swart GW. Activated leukocyte cell adhesion
molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls
matrix metalloproteinase activity. Cancer Res. 2005;65:8801–8.
18. Remmele W, Stegner HE. Recommendation for uniform definition of an
immunoreactive score (IRS) for immunohistochemical estrogen receptor
detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–40.
19. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased
expression of stem cell markers in malignant melanoma. Mod Pathol.
2007;20:102–7.
Donizy et al. Diagnostic Pathology  (2015) 10:86 Page 10 of 11
20. Swart GW, Lunter PC, Kilsdonk JW, Kempen LC. Activated leukocyte cell
adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma
cell clustering and cell migration? Cancer Metastasis Rev. 2005;24:223–36.
21. Swart GW. Activated leukocyte cell adhesion molecule (CD166/ALCAM):
developmental and mechanistic aspects of cell clustering and cell
migration. Eur J Cell Biol. 2002;81:313–21.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Donizy et al. Diagnostic Pathology  (2015) 10:86 Page 11 of 11
